undamentalytics Newsletter
Sign in

Starling Oncology, Inc. income statement

In fiscal 2025, Starling Oncology, Inc. reported revenue of $503m, up 27.8% on the year before, operating income of −$36.1m (a -7.2% margin) and net income of −$60.6m, or −$0.54 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue188203252324393503587
Selling, general and administrative4283120114108106111
Operating income−8−46−82−77−60−36−26
Interest expense00—77118
Net interest income—−0−4−7———
Income before tax−15−12−0−83−65−61−36
Income tax−0−1−0−00−00
Net income−14−110−83−65−61−36
Diluted EPS−$0.24−$0.16−$0.21−$0.92−$0.71−$0.54−$0.36
Diluted shares (average)59m66m81m74m75m92m101m
EBITDA−5−43−78−71−54−29−19

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CDNA vs STLNSTLN vs USPHCRVL vs STLN

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Starling Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Starling Oncology, Inc.